LENZ Therapeutics (LENZ) Change in Accured Expenses (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Change in Accured Expenses data on file, last reported at -$2.1 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 75.87% year-over-year to -$2.1 million in Q1 2026; TTM through Mar 2026 was $10.1 million, a 800.77% increase from a year earlier, with the FY2025 full-year figure at $11.0 million, up 247.12% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$2.1 million, down from $5.0 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for LENZ reached as high as $5.0 million in Q4 2025 and fell as low as -$7.2 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $605529.4 across 5 years, with a median of $1.2 million in 2022.
• Across the five-year window, Change in Accured Expenses slumped 4782.43% in 2024 and soared 518.45% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $453000.0 in 2022, then surged by 256.73% to $1.6 million in 2023, then dropped by 19.68% to $1.3 million in 2024, then surged by 287.44% to $5.0 million in 2025, then tumbled by 142.04% to -$2.1 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$2.1 million in Q1 2026, $5.0 million in Q4 2025, and $4.5 million in Q3 2025.